Validation of the Danish SARC-F in Hospitalized, Geriatric Medical Patients

Gade, Josephine; Beck, Anne Marie; Rønholt, Finn; Andersen, Hanne Elkjær; Munk, T.; Vinther, Anders

doi:10.1007/s12603-020-1453-x

Cited by 12 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results corroborate the ndings of others with different populations, regarding: a) a greater suspicion (screening) of sarcopenia in women than in men but not necessarily differences in identi cation (assessment) [15,[48][49][50]; b) a higher prevalence of suspected sarcopenia with SARC-Calf than with SARC-F [10,22]; c) a better diagnostic accuracy of sarcopenia of SARC-Calf compared to SARC-F having the EWGSOP2 as the gold standard [32,48,51]; d) a greater speci city than the sensitivity of screening instruments [10,32,47,48,[51][52][53]. The prevalence of sarcopenia increases with age in the elderly [27,54,55].…”

Section: Discussionsupporting

confidence: 90%

Screening for Sarcopenia - Performance of SARC-F and SARC-CalF in Older Adults from Northern Brazil

Lima

Ribeiro

Henriques‐Neto

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: To analyze the performance of SARC-F and SARC-CalF as screening tools for sarcopenia. Methods: The sample included 312 older people community-dwelling. Sarcopenia was defined as low handgrip strength (HGS) or low gait speed (GS≤0.8m/s). HGS was measured by dynamometry and GS by the 4-meter walking speed test. For HGS, the following criteria (C) were used to identify sarcopenia in men/women: CI: <27kg/16kg; CII: <35.5kg/20.0kg; CIII: grip over body mass index <1.05/<0.79; CIV: grip strength over total body fat <1.66/<0.65; CV: grip over bodyweight <0.45/<0.34. For sarcopenia screening, the SARC-F (≥4 points) and the SARC-Calf, (≥11 points) were used. Results: Sarcopenia was identified by SARC-F in 12.5% of men and 21.0% of women and by SARC-Calf in 27.7% of men and 40.0% of women. Taking GS and HGS as references, sarcopenia ranged between 15.2% (GS) and 75.0% (CII) for men and 27% (GS) and 66% (CIII) for women. The Kappa analysis revealed no agreement between the SARC-F and the various criteria for the identification of sarcopenia in men. The same lack of agreement was observed in women with some exceptions: CI=0.161±0.074; p=0.020; GS=0.209±0.076; p=0.003. Concerning the Cohen´s kappa between the SARC-Calf and the reference criteria of sarcopenia, the following coefficients were observed as significant for women: CI=0.201±0,069 p=0.003; CII=0.186±0,064 p=0.005; GS=0.273±0.068 p=0.0001; and for men: CII=0.139±0.053 p=0.021; GS=0.223±0.099 p=0.011. ROC curves revealed the SARC-Calf with acceptable discrimination and reasonable sarcopenia predictive capacity considering a cutoff value of 10.5 in both men (AUC:67.5%; p=0.022; Se=52.9%; Sp=76.8%) and women (AUC:72.4%; p<0.001; Se=63%; Sp=68.5%) with reference to GS. Conclusions: The SARC-Calf showed greater performance than the SARC-F for screen-ing sarcopenia in the population ≥ 60 years of age in the Amazonas, measured through walking slowness

show abstract

Section: Discussionsupporting

confidence: 90%

Screening for Sarcopenia - Performance of SARC-F and SARC-CalF in Older Adults from Northern Brazil

Lima

Ribeiro

Henriques‐Neto

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Screening for sarcopenia was done with the SARC‐F questionnaire in the Danish language. 17 The total score was calculated, and an SARC‐F score ≥4 indicated a risk for sarcopenia.…”

Section: Methodsmentioning

confidence: 99%

Prevalence of sarcopenia in patients with chronic intestinal failure—how are SARC‐F and the EWGSOP algorithm associated before and after a physical exercise intervention

Graungaard

Geisler

Andersen

et al. 2022

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Introduction Patients with chronic intestinal failure (IF) have a low degree of physical activity, decreased muscle mass, and decreased muscle strength, leading to a high risk of sarcopenia. We aimed to test the prevalence of sarcopenia by the use of SARC‐F and EWGSOP and to investigate the association between the two at baseline and after 12 weeks of an exercise intervention. Methods Thirty‐one patients with chronic IF completed 12 weeks of three weekly home‐based individualized exercise sessions. Body composition was measured by bioimpedance analysis and physical function by handgrip strength (HGS) and timed up‐and‐go (TUG). Sarcopenia was assessed by SARC‐F and EWGSOP. Multiple regression analysis was used to test for the association between the two tools. Results The prevalence of sarcopenia measured by EWGSOP was 59%. This prevalence did not change after the intervention. At baseline, 38.8% of patients were screened as at risk for sarcopenia by SARC‐F. This decreased to 29.0% after the intervention (P < 0.001). A statistically significant increase was achieved in muscle mass (P = 0.017) and muscle mass index (P = 0.016). Furthermore, both TUG (P = 0.033) and HGS (P = 0.019) improved. Conclusions Sarcopenia is prevalent in patients with chronic IF. EWGSOP finds more patients to be at risk of sarcopenia than SARC‐F but was not sufficiently sensitive to measure changes induced by the physical intervention. The significant change in SARC‐F may illustrate that patients, themselves, find an improvement in self‐perceived health.

show abstract

Sarcopenia: 2020

Morley

2021

The Journal of nutrition, health and aging

View full text Add to dashboard Cite

Validation of the Danish SARC-F in Hospitalized, Geriatric Medical Patients

Cited by 12 publications

References 48 publications

Screening for Sarcopenia - Performance of SARC-F and SARC-CalF in Older Adults from Northern Brazil

Screening for Sarcopenia - Performance of SARC-F and SARC-CalF in Older Adults from Northern Brazil

Prevalence of sarcopenia in patients with chronic intestinal failure—how are SARC‐F and the EWGSOP algorithm associated before and after a physical exercise intervention

Sarcopenia: 2020

Contact Info

Product

Resources

About